Shuwen Biotech to develop companion diagnostics for Bliss Bio
China-based Shuwen Biotech Co Ltd, a diagnostic company providing products and services has signed a partnership agreement with Bliss Biopharmaceutical Co, Ltd (Bliss Bio), a company involved in the discovery, development and commercialisation of biotherapeutics for medical needs.
Shuwen has agreed to develop companion diagnostics for Bliss’s oncology drug candidates; and to provide testing services in its CAP-certified central labs for BlissBio’s clinical trials. The terms of the partnership were not disclosed.
“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and CEO.
“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr Ziping Wei, CEO of BlissBio.
